Pre-clinical studies have demonstrated that the released payload of T-DXd, unlike T-DM1, is cell-membrane-permeable, and that T-DXd induces a bystander cytotoxic effect on cells in close proximity to targeted HER2-expressing tumour cells, regardless of their HER2 status [91]. The gene discussed is ERBB2; the disease is neoplasm.